文献速递传染病防控与疫情报告卫生政策与健康促进

鼠伤寒沙门菌载体曼氏血吸虫疫苗在慢性感染小鼠模型中的治疗活性

Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection.
PubMed 文献 · Vaccine · 2021-08-16

研究在慢性血吸虫感染小鼠中评估了一种以减毒鼠伤寒沙门菌YS1646递送曼氏血吸虫组织蛋白酶B(CatB)的疫苗,采用多模式免疫程序(第1、3、5天口服疫苗株,第1天肌注重组CatB)。接种后1个月寄生虫负荷较对照降低46.5–50.3%,2个月时相对降幅增至63.9–73.3%;血清抗CatB IgG显著升高且IgG1:IgG2c比值偏移,脾细胞呈现广泛的CatB特异性细胞因子/趋化因子应答。

要点

  • 该沙门菌载体CatB疫苗在慢性感染小鼠中显示治疗活性,2个月时虫负荷降幅达63.9–73.3%。
  • 接种后血清抗CatB IgG显著升高,并出现更平衡的TH1/TH2应答(IgG1:IgG2c比值偏移)。
  • 脾细胞在接种后1个月呈现广泛而强健的CatB特异性细胞因子/趋化因子应答。

核心结论

  • 减毒鼠伤寒沙门菌YS1646递送CatB的疫苗在慢性血吸虫感染小鼠中具有治疗活性,可降低寄生虫负荷并诱导体液与细胞免疫应答。

研究设计与样本

  • 在慢性感染小鼠模型中使用多模式免疫程序:第1、3、5天口服载CatB的YS1646株,第1天肌注重组CatB。

主要发现

  • 接种后1个月寄生虫负荷(虫数、肠道和肝脏虫卵数)较对照动物低46.5–50.3%。
  • 接种后2个月相对降幅进一步增至63.9–73.3%。
  • 接种后血清抗CatB IgG显著升高,IgG1:IgG2c比值偏移提示更平衡的TH1/TH2应答。
  • 接种后1个月分离的脾细胞呈现广泛而强健的CatB特异性细胞因子/趋化因子应答。

临床怎么用

  • 在血吸虫流行国家,该疫苗若兼具预防与治疗活性,理想用途是与吡喹酮群体治疗运动联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schistosomiasis is an important fresh-water-borne parasitic disease caused by trematode worms of the genus Schistosoma. With > 250 million people infected worldwide and approximately 800 million people at risk, the World Health Organization considers schistosomiasis to be the most important human helminth infection. Several prophylactic non-living vaccines are in pre-clinical and clinical development, but only one has been assessed for therapeutic effect in an animal model with modest results. Live attenuated Salmonella have multiple potential advantages as vaccine vectors. We have engineered an attenuated Salmonella enterica Typhimurium strain (YS1646) to produce a vaccine that targets the parasite digestive enzyme Cathepsin B (CatB). A multi-modality immunization schedule was used in chronically infected mice that included three oral (PO) doses of this CatB-bearing YS1646 strain on days one, three, and five as well as an intramuscular (IM) dose of recombinant CatB on day one. Parasite burden (worm count, intestinal and liver egg numbers) were 46.5 - 50.3% lower than in control animals 1 month post-vaccination and relative reductions further increased to 63.9 - 73.3% at 2 months. Serum anti-CatB IgG increased significantly after vaccination with the development of a more balanced TH1/TH2 pattern of response (ie: a shift in the IgG1:IgG2c ratio). Compared to control animals, a broad and robust CatB-specific cytokine/chemokine response was seen in splenocytes isolated 1 month post-vaccination. A vaccine that has both prophylactic and therapeutic activity would be ideal for use in conjunction with mass treatment campaigns with praziquantel in schistosome-endemic countries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hassan AS, Perera DJ, Ward BJ, et al. Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection. Vaccine. 2021. PMID: 34412919. doi:10.1016/j.vaccine.2021.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。